Re: New Variant

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: New Variant

in response to

Re: New Variant

KayakerBC

posted on Nov 28, 2021 04:45PM

https://www.nytimes.com/2021/11/26/science/merck-molnupiravir-antiviral-covid-pill.html

"The pharmaceutical company Merck said on Friday that in a final analysis of a clinical trial, its antiviral pill molnupiravir, reduced the risk of hospitalization and death among high-risk Covid patients by 30 percent, down from an earlier estimate of 50 percent. ....... Fluvoxamine, a common and inexpensive antidepressant, appears to be about as effective as molnupiravir. (bolding added)

"Pfizer’s antiviral pill, Paxlovid, which was found in a clinical trial to cut the risk of hospitalization and death by 89 percent, could become available within weeks." Let's see if, in the final analysis, this holds true!!!

Note of interest: "Monoclonal antibody drugs, which are typically administered intravenously in the United States, have been found to reduce hospitalizations and deaths by at least 70 percent."